中國核能科技(00611.HK):預計年度純利減少不超35%
格隆匯 2 月 26日丨中國核能科技(00611.HK)發佈公吿,與2019年同期的純利相比,預期集團截至2020年12月31日止年度的末期業績錄得的純利將減少不超過35%。
公吿稱,減少主要源於各項綜合影響所致,其中包括:集團的工程、採購及建設(“EPC”)以及諮詢及整體建設分類預期於該年度將錄得純利減少,主要由於以下原因:(i)冠狀病毒疫情導致EPC項目數量減少並拖慢現有EPC項目的進度,亦影響2020年太陽能EPC市場的發展;(ii)不確定性因素以及商業及經濟環境惡化導致年內招標及推行的新項目減少;及(iii)推出平價上網及競價上網使太陽能項目的總成本整體減低,促進市場競爭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.